Treatment with sunitinib, an RTK inhibitor, inhibited Ret signalling and rescued differentiation in both mouse myoblasts expressing DUX4 and FSHD patient-derived myoblasts. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.